Description of goals of treating atrial fibrillation. Rhythm vs rate control and anticoagulation.
Просмотров: 680 Diego Belardi
"New Anticoagulants for Stroke Prevention in Atrial Fibrillation" Christian Ruff, MD Treatment Options for Atrial Fibrillation and VTE March 4th, 2013 Brigham and Women's Hospital Boston, MA
Просмотров: 10515 NAThrombosisForum
While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.
Просмотров: 3183 MD Magazine
In this video we try to explain two of the key issues for the management of atrial fibrillation. 1.The first issue is the issue of heart rate control versus heart rhythm control. Will your physician try to just control your heart rate or try to flip your rhythm back in to sinus rhythm from atrial fibrillation? With heart rate control our goal is to try to control the heart rate only. Thus the patient could still be in atrial fibrillation however heart rate is brought under control (60-110 bpm) with medications like beta blockers- metoprolol and calcium channel blockers like diltiazem etc. By rhythm control the physician tries to reset the heart into into sinus rhythm from atrial fibrillation. This can be done with the help of medications and is called as chemical cardioversion. Or it can be done by electrical shock also known as electrical cardioversion. Medications that can be used to keep the patient in the rhythm. These medications include, flecanide, sotalol or amiodarone etc. 2. The second key issue in the management of atrial fibrillation is prevention of stroke. Stroke is a deadly complication of atrial fibrillation. The first question that arises is what is the risk of stroke in a given patient with atrial fibrillation. A patients risk of stroke can be calculated by using an abbreviation called CHAD2VASC2 (explained in the table). Blood thinners (like Coumadin or newer agents like xeralto/apixaban/rivaroxaban) are recommended for patients with a score more than 2. For a score of zero usually no blood are recommended and for patients with the score of one either blood thinner or are aspirin as recommended. If you like this video and would like to see more of such patient educational videos go to our website www.patienteducationpro.com.
Просмотров: 1526 PatientEducationPro
Join our channel by subscribing here. If you have enjoyed our video, please like it and leave a comment about what other videos you may be interested in. Your help in creating great, relevant content is greatly appreciated. Discover everything patients should know about the blood thinner Coumadin (Warfarin). I cover the mechanism of action against vitamin K, the conditions it treats (including atrial fibrillation and deep vein thrombosis a.k.a DVT), the INR and how it should be monitored. This video describes the role of Warfarin in managing atrial fibrillation. Also included are modern day pros and cons of still using this medication that has been available for well over 50 years. Transcript: Thank you for visiting doctor AFib, I'm Dr. Morales. In today's video segment we're going to be talking about a blood thinner that has been on the market for well over 50 years, known as Warfarin or also goes by the brand name of Coumadin.Yes, it was first advertised and marketed as a rat poison way back in the 1940s. But starting in the 1950s it began to be approved for human use as a blood thinner.Nowadays it's actually used for several purposes, including for reducing the risk of stroke for atrial fibrillation, but also for treating deep venous thrombosis, pulmonary embolism as well as an anticoagulant for mechanical heart valves. Starting in the late 1980s and into the 1990s there were several clinical trials comparing Warfarin with aspirin for reducing the risk of stroke for atrial fibrillation.Several times Warfarin was shown to be superior for reducing the risk of stroke.In meta-analysis where they combined data from several clinical trials, it showed that Warfarin reduces the risk of stroke by about 66 percent. However, there are a lot of nuances when it comes to managing somebody who has taken Warfarin. First of all, not everybody's dose is the same based on how individuals metabolize the medication. There's a blood test called an INR, which helps your doctor monitor your Warfarin level to find the right dosage for you.At the beginning, very frequently people will have the blood tested every week until you find the correct dosage for you.After that stage, it may be only checked about once a month The target level on the blood test for most people is between a level between two to three in that INR blood test. However, there's been several studies that have shown that the amount of time people are actually within that recommended range can range anywhere from 50 to 70 percent of the time which shows that at least 30% of the time or even more patients are not within the recommended range of that INR level. Listen to the video for more Read my blog posts at http://www.DrAFib.com
Просмотров: 302 Dr. AFib
If you've looked at the research regarding cardiac arrhythmias then you might have noticed that all the doctors and researchers are focused on the heart and the nodes that control heart function, however, Dr. Bergman explains the one thing everyone is missing... The Autonomic Nervous System. Dr. Bergman's Website https://drjohnbergman.com/ Dr. Bergman's Facebook page: https://www.facebook.com/drjohnbergman/ Dr. Bergman's Clinic: http://bergmanchiropractic.com 714-962-5891 Office Hours: Monday 5:15am 6:00pm Tuesday 6:30am 6:00pm Wednesday 5:15am 6:00pm Thursday 5:15am 6:00pm Friday 6:30am 6:00pm Saturday Closed Closed Sunday Closed Closed Dr. Bergman is available for Skype and Phone consultations which you can schedule by using the link below: https://drjohnbergman.com/online-consultations/booking-consultations/ For Media and Business Inquires contact: firstname.lastname@example.org
Просмотров: 150159 Dr. John Bergman
Rich Gordon and Dan McCollum discuss differences between treating Atrial Fibrillation with rapid ventricular response with rate control versus cardioversion. Rich favors rhythm control a bit more than Dan who slightly prefers rate control. Rich makes some excellent points about the need to resuscitate to maintain correct rhythm and to remember the use of heparin if you plan to cardiovert.
Просмотров: 1568 Daniel McCollum
Anne O'Connor, MD and Jennifer Wright, MD co-present a lecture about clinical management of atrial fibrillation. Dr. O'Connor is an Associate Professor (CHS) whose clinical interests include critical cardiology, reducing readmissions for heart failure and acute myocardial infarct patients, and cardiovascular imaging. Dr. Wright is a Clinical Assistant Professor who specializes in cardiology and electrophysiology. Both are members of the Division of Cardiovascular Medicine in the Department of Medicine at UW-Madison. The title of their June 16, 2017 Grand Rounds talk is "Atrial Fibrillation: Can We Organize the Chaos?" University of Wisconsin Department of Medicine Grand Rounds are presented throughout the academic year and are intended for health care professionals and medical researchers. Unless otherwise indicated, Grand Rounds occurs in the William S. Middleton Memorial Veterans Hospital auditorium, Room A1028, Madison, Wisconsin. All faculty and staff are invited and encouraged to attend. For more information on the Grand Rounds lecture series, visit http://www.medicine.wisc.edu/dom/medicine-grand-rounds
Просмотров: 2161 UW Department of Medicine
Houston Methodist DeBakey Heart & Vascular Center Grand Rounds “Rate Control versus Rhythm Control for Atrial Fibrillation” Fred Morady, MD October 6, 2016
Просмотров: 1521 DeBakey Institute For Cardiovascular Education & Training
http://www.stopafib.org StopAfib.org interviews Dr. Eric Prystowsky of St. Vincent's Hospital in Indianapolis, Indiana Find more on Dr. Prystowsky: http://www.stopafib.org/newsitem.cfm/NEWSID/417 Find more on rate control for the treatment of afib at: http://www.stopafib.org/rate-control.cfm In this video, Dr. Prystowsky discussed the proper application of rate control as a method of controlling atrial fibrillation, as well as which patients may be most appropriately treated with rate control. Dr. Prystowsky currently serves as the Director of the Clinical Electrophysiology Laboratory at St. Vincent's Hospital, and as a Consulting Professor of Medicine at Duke University. He is a former President of the Heart Rhythm Society, and is one of the leading clinical cardiac electrophysiologists in the world.
Просмотров: 3461 StopAfib
Researchers have linked a widely used heart drug to increased risk of dementia. Warfarin is a blood thinner used in the treatment of atrial fibrillation, an abnormal heart rhythm that affects millions of people in the U.S. Researchers at the Intermountain Medical Center Heart Institute tracked more than 10,000 patients who took warfarin long-term, both for atrial fibrillation and for other conditions. The researchers found that patients with atrial fibrillation experienced higher rates of dementia and Alzheimer's. Within eight years, close to 6 percent of patients taking warfarin for atrial fibrillation developed dementia, compared to less than 2 percent of those taking warfarin for other reasons. This is the first study to detail the dementia risks of warfarin. Doctors warn the connections between blood thinners, atrial fibrillation and dementia are still not clearly understood. The study's lead author says because doctors are only now learning about the risks, "only those that absolutely need blood thinners should be placed on them long-term." This video includes clips from the National Institutes of Health and Intermountain Medical Center Heart Institute and images from Gonegonegone / CC BY SA 3.0. Newsy is your source for concise, unbiased video news and analysis covering the top stories from around the world. With persistent curiosity and no agenda, we strive to fuel meaningful conversations by highlighting multiple sides of every story. Newsy delivers the news and perspective you need without the hype and bias common to many news sources. See more at http://www.newsy.com/ Like Newsy on Facebook: http://www.facebook.com/newsyvideos/
Просмотров: 791 Newsy
http://www.stopafib.org StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: http://www.stopafib.org/newsitem.cfm/NEWSID/397 Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban (Xarelto), which was recently approved by the FDA, and talked about the results of the two trials of apixaban (Eliquis), AVERROES and ARISTOTLE, against aspirin and warfarin, respectively. He also mentioned edoxaban, which should finish trials in 2012, and that we now have a year of results in clinical practice with dabigatran (Pradaxa). He also mentioned that the new drugs have all shown better results than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the brain). He confirmed that patients will have a lot of new choices soon, but that cost will continue to be an issue. Dr. Singer is a Professor of Medicine at Harvard Medical School, Professor of Epidemiology at the Harvard School of Public Health, and Chief of the Clinical Epidemiology Unit at Massachusetts General Hospital.
Просмотров: 3041 StopAfib
Heart rate vs. rhythm control vs. rhythm restoration was the focus of Dr. Paul Wang’s talk at Piedmont Heart’s Napa Valley Cardiology Conference. Dr. Wang, director of Stanford’s Cardiac Arrhythmia Service, discusses the overall treatment guidelines for the management of patients with atrial fibrillation (AF) and reviews the recent 2017 AF ablation guidelines with “an important new emphasis on surgical ablation for our field.”
Просмотров: 44 Piedmont Heart Institute
Teresa Tsang, MD, FRCPC, FACC, FASE, Vancouver, BC; John Cairns, MD, FRCPC, FRCP (Lond), FCAHS, FACC;Jason Andrade, MD, FRCPC Atrial fibrillation (AF) is the most common arrhythmia managed by physicians. Most patients with AF or atrial flutter (AFL) have poor quality of life due to the symptomatology of the disease, making the management strategy a key component of symptoms improvement, reduction of hospitalizations, and prevention of further complications, such as stroke. The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Program has generated a comprehensive series of documents regarding the management of AF between 2010 and 2016.
Просмотров: 10527 CFPCMedia
Atrial fibrillation is a common heart condition that causes an irregular and often rapid heart rate. Control of heart rate can be achieved with different medications, but we currently lack evidence for the best treatment, making it difficult to choose the right medication for individual patients. The RATE-AF trial is designed to compare two strategies of rate-control, to see which improves quality of life and heart function. Patients with atrial fibrillation are closely involved with the design and management of the research study. Together, we hope to improve the lives of patients with atrial fibrillation and give doctors more evidence about how to treat their patients. For more information, please go to http://www.birmingham.ac.uk/rateaf. RATE-AF is sponsored by the University of Birmingham and funded through a Fellowship programme by the National Institute for Health Research (NIHR), a UK government body that coordinates and funds research for the National Health Service. Video filmed and edited by Daniel Coley and Sarah Tholin (University of Birmingham). Music by Podington Bear: http://freemusicarchive.org/music/Podington_Bear/Joyful/PeasCorps
Просмотров: 485 RATE-AF
Mintu Turakhia, MD, MAS, discusses the use of Aspirin and why it may or may not be effective treatment for Atrial Fibrillation. Connect with other patients and learn how they manage AFib at: http://spr.ly/60578YV0J
Просмотров: 159 American Heart Association
Dr. Alo discusses atrial fibrillation treatment algorithms including many of the newer rate and rhythm control drugs. Also discusses the novel anticoagulation options. Target audience is informed patients and medical professionals. hhtp://MohammedAlo.com
Просмотров: 10483 Mohammed Alo
An in-depth conversation between Pentucket Medical cardiologists Seth Bilazarian and Sunny Srivastava, focusing on a newly released medicine to reduce the risks of atrial fibrillation. The latest among recently approved blood thinners, Eliquis joins Pradaxa and Xarelto as an alternative to Coumadin, a drug that has been in use since the 1950s. Like Pradaxa and Xarelto, Eliquis has been shown to reduce risk of stroke and bleeding, as well as mortality. All the new drugs eliminate the need for regular blood testing that Coumadin necessitates.
Просмотров: 27291 PentucketMedical
http://nevadacardiology.com | Nevada Cardiology Associates is the leader in cardiovascular care in the Las Vegas. Our commitment is to deliver the best personalized cardiovascular care, emphasizing compassion, friendliness, clear communication, prompt service, and emergency availability. Our eight Las Vegas Cardiologists and large support staff provide a full spectrum of cardiology services. • Formed in 1989 and acknowledged for our innovative cardiovascular practices • We are an 8-member group of highly qualified and diversely trained cardiologists • Voted by Las Vegas residents TOP DOCTORS in 2016 ########### What is Atrial Fibrillation? ############# Original post here: http://nevadacardiology.com/what-is-atrial-fibrillation/ Atrial fibrillation is the most common sustained heart rhythm in the United States affecting about 3 million Americans. Instead of beating normally, the upper chambers quiver or fibrillate. The upper chambers no longer fill the lower chambers with blood and heart output can be reduced by 20-40%. During atrial fibrillation the upper chambers send about 600 impulses a minute down to the lower chambers. While the lower chambers do not beat 600 times a minute, they can still beat very fast and irregularly. Over time this can cause the important lower pumping chambers to fail. Possibly the worst complication of atrial fibrillation is stroke. When the upper chambers stop contracting, blood can stagnate and form a clot. This clot can break off and go anywhere in the body including the brain. 75% of strokes associated with atrial fibrillation leave a patient in a nursing home or are fatal. Atrial fibrillation that lasts more than 48 hours will put a patient at risk for stroke. The stroke risk is 5% per year for ongoing atrial fibrillation. The stroke risk becomes higher for older patients. Generally, the risk of stroke can be lowered to 1% per year or less with oral blood thinners such as coumadin, Pradaxa or Xarelto. There is an additional 1% per year risk of serious bleeding with blood thinners, but generally the benefits outweigh the possible complications for most people. Pradaxa may be slightly superior to coumadin which was the standard for many years. The use of coumadin (also called warfarin) requires frequent monitoring with lab work to make sure the blood is not too thick or too thin. Xarelto and Pradaxa do not have this monitoring requirement. Atrial fibrillation patients may be converted back to normal sinus rhythm with medications, an electrical cardioversion (shock) or they may convert spontaneously on their own. It is important that their blood be blood be therapeutically thin for 3 weeks prior to a cardioversion or that blood thinner be started and clot ruled out with a transesophageal echo. Atrial fibrillation always comes back at some point and 9 out of 10 patients cannot tell when an episode of atrial fibrillation first starts. Their presenting symptom may be shortness of breath/heart failure or even a stroke several weeks after their abnormal rhythm begins. There are ways of checking daily for atrial fibrillation, but no method is 100% accurate. After a person is converted back to normal rhythm, it is critical that they remain on blood thinners for at least one month and, in most cases, much longer. There is still a significant stroke risk after the heart converts back to normal from a clot dislodging. Individual treatment for atrial fibrillation is dependent on many factors and should be discussed with your cardiologist/electrophysiologist. If you would like to speak to an expert cardiologist about treating AFib please schedule an appointment by calling 702-475-5115 or using our online form here. Nevada Cardiology Associates welcomes any questions you may have about our services. Contact our staff at our Maryland or Tenaya locations for questions. Connect With Us: https://www.facebook.com/NevadaCardio... https://twitter.com/nvheartdocs https://plus.google.com/+Nevadacardio... https://www.pinterest.com/nvheartdocs/ #bestheartdocsinvegas #topcardiologist #topdocsnv Office Locations Nevada Cardiologist Associates 3121 S Maryland Pkwy #512 Las Vegas, NV 89109 (702) 903-2013 New Patients (702) 796-7150 Office (702) 736-3764 Fax Nevada Cardiologist Associates 3150 North Tenaya Way #460 Las Vegas, NV 89128 (702) 903-1942 New Patients (702) 796-7150 Office (702) 736-3764 Fax
Просмотров: 55 Nevada Cardiology
Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Some people refer to AF as a quivering heart. An estimated 2.7 million Americans are living with AF.
Просмотров: 22382 American Heart Association
Dr. Kneller discusses discuses treatment strategies for atrial fibrillation. Considerations include rhythm control (stopping and preventing atrial fibrillation) and rate control (slowing down the rapid heart rate caused by atrial fibrillation, without attempting to restore a normal rhythm), and whether systemic anticoagulation medication (ie, Xarelto, Eliquis, Pradaxa, or warfarin) is needed. Anti-arrhythmic medications (ie, flecainide, propafenone, sotalol, tikosyn) or catheter ablation are used to restore normal rhythm.
Просмотров: 3214 JamesKnellerMD
http://www.stopafib.org StopAfib.org interviews Dr. Peter Kowey See the full transcript at: http://www.stopafib.org/newsitem.cfm/NEWSID/255 In this video interview at Boston Atrial Fibrillation Symposium 2010, Dr. Peter Kowey talked about a number of exciting new things in the atrial fibrillation world, including the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a replacement for amiodarone, atrial selective drugs, and coming replacements for Coumadin (warfarin).
Просмотров: 1289 StopAfib
Dr. S Arthnari performs on The main cause of strokes in the elderly is acquired Aortic Stenosis
Просмотров: 21 Revolution Talk
Sunil Rao John Alexander
Просмотров: 137 Duke Clinical Research Institute
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions. Researcher and electrophysiologist Jared Bunch, MD, with the Intermountain Medical Center Heart Institute, explains the study, which was presented at the American Heart Association Scientific Sessions in New Orleans.
Просмотров: 69 Healthy Dialogues
Rate and Rhythm Control for Atrial Fibrillation Gregory Piazza, MD North American Thrombosis Forum (NATF) Thrombosis Prevention Forum 2011 April 28, 2011 Boston, MA
Просмотров: 1419 NAThrombosisForum
Dr Matthew Fay (GP and AF specialist) and Brendan Young (Patient representative on West Midland Clinical Senate) speak about the importance of anticoagulation for stroke prevention in patients with AF
Просмотров: 777 Stroke Association
Former Emmaus teacher Buzz Hill developed atrial fibrillation (AFib) in his late seventies. He experienced a stroke and later, also suffered a brain bleed as a result of taking the blood thinner Warfarin (Coumadin.) Many patients with AFib are at an increased risk of stroke due to blood clots which form in a pocket of the heart called the left atrial appendage (LAA). In this video, Buzz and his wife Carolyn share how they made the decision to have a device called Watchman implanted in a catheter-based procedure at Lehigh Valley Health Network. He returned home the day after the procedure, and felt well enough to return to the outdoors and enjoy one of his favorite past times, hunting.
Просмотров: 561 Lehigh Valley Health Network
ford brewer md mph . PrevMedHeartRisk.com I had my own episode of a fib. I thought I'd had these before. I got an iphone device called Kardia. It allows people to check their own rhythm strip. You don't have to be a doctor to read this. It gives you an indication. Also, you can send the reading off to a professional for an interpretation. I woke up at 2 am last Sunday AM. It felt like there was a fish jumping in my chest. I took several episodes of readings. It appears to be a fib. There was an irregularly irregular heart rhythm. The strip showed no p wave, indicating chaos within the atria. My ventricular response was in the range of 140 to160 beats per minute. I also had a couple of aberrant ventricular responses. I'll have to get this worked up. I have several risk factors: endurance running 4 q 25 gene ( the "atrial fib" gene) age 60 alcohol 6-8 drinks per week. I may end up on Xarelto. The New Oral Anti Coagulants ( NOACs) are demonstrating to be better than aspirin or coumadin for stroke prevention. I'll also look at the WATCHMAN and other devices. But I don't think they're ready yet. About Dr. Brewer - Ford Brewer is a physician that started as an Emergency Doctor. After seeing too many patients coming in dead from early heart attacks, he went to Johns Hopkins to learn Preventive Medicine. He went on the run the post-graduate training program (residency) in Preventive Medicine at Hopkins. From there, he made a career of practicing and managing preventive medicine and primary care clinics. His later role in this area was Chief Medical Officer for Premise, which has over 500 primary care/ prevention clinics. He was also the Chief Medical Officer for MDLIVE, the second largest telemedicine company. More recently, he founded PrevMed, a heart attack, stroke, and diabetes prevention clinic. At PrevMed, we focus on heart attack and stroke and Type 2 diabetes prevention by reducing or eliminating risk through attentive care and state-of-the-art genetic testing, imaging, labs and telemedicine options. We serve patients who have already experienced an event as well as those have not developed a diagnosis or event. Our team of senior clinicians includes internationally recognized leaders in the research and treatment of cardiovascular disease, preventive medicine and wellness. We also provide preventive medicine by telemedicine technology to over 30 states. Contact Dr. Brewer at email@example.com or visit http://prevmedheartrisk.com.
Просмотров: 1581 Ford Brewer
A discussion of the controversies surrounding the RE-LY and ROCKET-AF trials, which led to the initial FDA approvals of dabigatran (Pradaxa) and rivaroxaban (Xarelto) respectively. Please note that in the 2 years since this video was posted, additional studies have been published which support the use of these drugs. I leave the video up because the issues discussed are still relevant. However, if you are a layperson, please do NOT stop taking your Xarelto or Pradaxa just because you watched this video. Instead, discuss your concerns with your physician. There are more than one alternative anticoagulants out there. I declare that I have no conflicts of interest, and receive no compensation from the pharmaceutical or device industries. Original RE-LY Trial: http://www.ncbi.nlm.nih.gov/pubmed/19717844 Original ROCKET-AF Trial: http://www.ncbi.nlm.nih.gov/pubmed/21830957 BMJ Criticisms of Dabigatran RE-LY: http://www.ncbi.nlm.nih.gov/pubmed/25056265 http://www.ncbi.nlm.nih.gov/pubmed/25055831 http://www.ncbi.nlm.nih.gov/pubmed/25055829 BMJ Criticism of ROCKET-AF and Rivaroxaban: http://www.ncbi.nlm.nih.gov/pubmed/26843102 Recent media coverage of dabigatran and RE-LY: https://www.washingtonpost.com/news/federal-eye/wp/2015/10/15/fda-was-lax-and-kowtowed-to-drugmaker-in-review-of-controversial-blood-thinner-watchdog-says/ http://www.nytimes.com/2014/02/08/business/new-emails-in-pradaxa-case-show-concern-over-profit.html http://www.nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html Recent media coverage of rivaroxaban and ROCKET-AF: http://www.nytimes.com/2016/02/23/business/fda-asks-if-faulty-blood-monitor-tainted-xarelto-approval.html?_r=0 http://www.cbsnews.com/news/did-heart-drug-makers-withhold-data-from-medical-journal/
Просмотров: 34589 Strong Medicine
Dr. Elad Maor, an Interventional Cardiology Fellow at Mayo Clinic in Rochester, MN, shows in his article appearing in the December 2016 issue of Mayo Clinic Proceedings, that healthy patients undergoing stress tests who were slow to recover normal heart rates within 5 minutes were more likely to develop new-onset atrial fibrillation. He suggests this inexpensive test can be used to predict cardiovascular disease and mortality risks. Available at: http://tinyurl.com/hae89q7
Просмотров: 185 Mayo Proceedings
Learn fast with Dr. Aman Arora's short snaps! www.aroraMedicalEducation.co.uk 👉 Flagship Facebook Medical Education group: https://m.facebook.com/groups/1571643289740957 👉 Instagram: @arorameded (https://www.instagram.com/arorameded/) 👉 Twitter: @arorameded (https://mobile.twitter.com/arorameded?lang=en) 👌 This video: 💥💥💥 60 seconds on when you may consider rhythm-control for AF instead of rate-control Source/details: https://cks.nice.org.uk/atrial-fibrillation#!scenarioclarification *not for medical advice* www.aroraMedicalEducation.co.uk 💥 Immersion Courses 💥 Mock Exams 💥 Live Webinars 💥 Online Training 💥 One-to-one Sessions 💥 Revision Posters *All videos are for educational purposes only and are not to be used for medical advice. Guidance is aimed to be relevant and up-to-date at time of release*
Просмотров: 749 Aman Arora
Dr David Whalley, Cardiologist at Royal North Shore Hospital, talks about the medical management of atrial fibrillation. Presentation delivered at the Structural Heart Disease Australia Left Atrium Symposium 23 July 2016.
Просмотров: 635 Structural Heart Disease Australia
Dr Paul Dorian explains the use of warfarin to reduce stroke risk for people with atrial fibrillation Part of an unscripted video series "Speaking from experience" developed by the Heart and Stroke Foundation This video may be freely downloaded and used under the terms of the Creative Commons attribution-non-commercial-no derivatives license.
Просмотров: 218 Heart and Stroke
http://www.stopafib.org To be notified when new conference videos are posted, or for the latest afib news, sign up at http://www.stopafib.org 2015 Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference In the Partnering with Your Healthcare Providers session at the 2015 Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference, Dr. Robert C. Kowal, MD, PhD, FHRS spoke about getting the most from your doctors, including: • What kind of doctor is likely to manage your care • Doctor taking primary responsibility for your AF depends on how it was discovered [1:38] • Doctor taking primary responsibility based on how you feel [2:09] • What is involved in managing afib care • Care components: stroke prevention, rate management, symptom/rhythm management [3:42] • What prompts referral [4:22] • Patient age, complex medical conditions, history of HD, high heart rate difficult to control, ongoing symptoms despite treatment • AFFIRM trial justifies minimal approach to AF [5:25] • Pieces of atrial fibrillation management [6:40] o Stroke prevention o Rate control o Rhythm management o Timing can be critical o Comorbid conditions • When do patients typically get referred to specialists, and [10:36] • What are the challenges with seeing specialists [11:49] Following Dr. Kowal, Mellanie True Hills discussed communicating with your healthcare providers and resources that can help patients. • Communicating with your doctor [13:59] • Resources – patient care [19:29] • Communications between patients and healthcare providers [20:25] In a subsequent dialogue, Dr. Kowal and Mellanie discussed the following topics: • How to know if you have the right doctor [21:40] • How much variation doctors see in AF patient symptoms [22:32] • What to do if the relationship is just not working [28:30] • What patients do that drive doctors nuts [30:30] • The difficulty of getting patient records [31:55] • How doctors and patients can use mobile health together, and [33:51] • What is the ideal “engaged patient” like [35:43] Video watching time is approximately 45 minutes. Dr. Robert Kowal graduated from Yale University and received his MD and PhD degrees from UT Southwestern Medical Center. He completed his medical internship, residency, and cardiology fellowship at Harvard Medical School/Brigham and Women’s Hospital and went on to study cardiac electrophysiology. He currently practices at Baylor Heart and Vascular Hospital. While performing a broad spectrum of device implantation procedures, from pacemakers to multi-lead defibrillators, his main focus is the management of complex arrhythmias such as atrial fibrillation and ventricular tachycardia. His approaches involve both non-invasive medical therapy and catheter-based ablation procedures. He has been and is currently involved in research on many cutting-edge technologies including cryoballoon ablation and FIRM mapping for atrial fibrillation, left atrial appendage closure and the role of renal denervation in the treatment of arrhythmia. He has taken a national leadership role serving on the Board of Trustees at the Heart Rhythm Society and is on the editorial board of several scientific journals. Transcript http://www.stopafib.org/newsitem.cfm/NEWSID/554/
Просмотров: 1205 StopAfib
5:45 Lecture Start 6:41 Atrial Fibrillation: cause 10:45 Right Atrium causes PE, Left Atrium causes Stroke 14:00 Anticoagulants, not thrombolytics: aspirin, warfarin 15:00 Treatment A Fib: anticoagulants, antiarrhythmia drugs, and heart rate lowering drugs 16:00-17:58: The A fib assignment 18:45 Angina in movies 19:36 Stable Angina: definition 20:50 Angina and MI pain differs in men and women 21:30 Dead lady in the bathroom story 22:30 Cause of angina 23:08 I attempt to draw a picture and it doesn't appear until 26:21 26.40 Drawing of angina oxygen supply and demand 28:30 Arteriosclerosis reduces ability of coronary vessels to dilate 29:50 Strategies: 1: Dilate coronary vessel 30:40: 2. Keep clots from forming 31:50 3. Reduce oxygen consumption (reduce heart rate, and reduce preload and afterload) 34:45 Unstable angina and various heart attacks (coronary syndromes) 36:00 Aspirin 39:25 Warfarin: Too little, too much, and misery of managing it 42:00 Heparin 44:00 NITRATES and nitroglycerin 44:38 Special storage of nitroglycerin and tubing 45:50 Nitrate tolerance: remove patch/paste at night 47:38 Nitrates and first pass metabolism (remember ORAL dose will be much higher than doses via other routes) 49:45 How to give nitroglycerin pills for chest pain (q 5 minutes x 3) 51:00 Nitrates dilate blood vessels, and gives patient a headache 52:15 Orthostatic hypotension 53:39 Reflex Tachycardia 54:35 Erectile Dysfunction 55:40 How viagra+nitrates kill you 56:15 Sexy Monkey 57:00 Isosorbide dinitrate 57:10 beta-blockers 58:13 Brick under the accelerator pedal 59:09 Hollywood calls. Skip to 59:26 59:26 beta-blocker makes an upper limit beyond which the heart rate cannot go 59:58 Old granny with 20 cats and vacuuming: how beta-blocker prevents patients from becoming deconditioned 1:03:00 Propranolol Black Box warning (is also black box warning for all beta-1 blockers used for angina) 1:05:56 (SIDE NOTE about alpha-1. NorEpi and Epi binding alpha-1 receptors do NOT constrict coronary vessels. That would be bad. Assume there are no alpha-1 receptors on coronary vessels 1:08:00 Calcium levels and strength of contraction 1:09:20 Calcium Channel Blocker (CCB) lowers calcium inside muscle, and so the muscle relaxes. Includes smooth muscle in arteries 1:10:22 CCB slows electrical conduction in the atrium and AV node 1:11:40 EPIC constipation 1:12:50 My gross mnemonic for remembering CCBs cause constipation 1:13:59 SIDE NOTE Drugs contraindicated in pure LVHeartFailure: CCBs, propranolol and mannitol 1:15:45 Types of CCBs 1:17:00 Fast-acting nifedipine and reflex tachycardia 1:19:00 morphine and oxygen 1:20:00 Plans for next week, homework for next week and plans for the exam Okay. This is my first time trying to stream. So it is a bit choppy and I look a bit like the robot lady in the bottom of Starcraft II. Which is cool but a little distracting. This talk will consist of a brief lecture about Atrial Fibrillation, and then I'll talk about Angina and the drugs we use to treat angina.
Просмотров: 526 Linnea Boyev
Cardiovascular Fellows' Bootcamp 2016 RHYTHM SESSION "Atrial Fibrillation and Stroke Prevention" Miguel A. Valderrábano, MD Sunday, August 21, 2016 DICET@Houstonmethodist.org
Просмотров: 1846 DeBakey Institute For Cardiovascular Education & Training
T271 Canadian Cardiovascular Society Atrial Fibrillation Guidelines Management of AF for the family physician Dr Alan Bell (1)
Просмотров: 334 CFPCMedia
Explains (using a pig heart) why people that have atrial fibrillation (A-fib, or AF) usually take medication to help prevent blood clotting.
Просмотров: 809 Ren Hartung
Atrial fibrillation including management
Просмотров: 23 Azib Zahid
http://www.theheart.org/editorial-program/1014771.do New agents and interventions are paving the way for revised modalities in the evaluation and management of patients with atrial fibrillation--the most common arrhythmia, which affects an estimated 2.2 million people in the US alone. Join Drs Alpert and Delascio Lopes for a review of the latest findings, including promising new antithrombotic and anticoagulation agents, stroke prevention, the ongoing rhythm-vs-rate-control debate, ATHENA, RE-LY, and CABANA, as well as the CHADS2 score.
Просмотров: 169 theheartorg
Student: AMANDA ZAMBRANO SANTOS
Просмотров: 175 Amanda Zambrano
Sarah Spinler, PharmD, professor of clinical pharmacy at the Philadelphia College of Pharmacy, explains why some patients with atrial fibrillation should be prescribed a new oral anticoagulant (NOAC) instead of warfarin.
Просмотров: 356 Pharmacy Times TV